Chester County News and Community Website
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) released its financial results for the fiscal year ending December 31, 2024, while highlighting progress in clinical development, partnerships, and new strategic …
Windtree Therapeutics Reports 2024 Financial Results and Strategic Developments Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced it has successfully regained compliance with The Nasdaq Stock Market LLC’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). This ensures …
Windtree Therapeutics Regains Nasdaq Compliance Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has entered a License and Supply Agreement with Evofem Biosciences, Inc. (OTCQB: EVFM) to become the sourcing partner for Evofem’s FDA-approved, hormone-free contraceptive, …
Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI® Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application number …
Windtree Therapeutics Secures Patent for Istaroxime IV Formulation in Acute Heart Failure Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has filed a national phase patent application with the Indian patent office for its innovative heart failure treatment, Istaroxime. The application, entitled “ISTAROXIME …
Windtree Therapeutics Files Patent Application in India for Istaroxime, Advancing Arrhythmia Treatment Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced a 1-for-50 reverse stock split of its common stock. The company’s board approved the move following authorization granted by stockholders during …
Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) showcased encouraging results from the Phase 2b SEISMiC study of istaroxime, its novel investigational therapy for early cardiogenic shock, at the Technology and …
Windtree Therapeutics Highlights Promising Phase 2b Results for Istaroxime Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the issuance of a new patent in Japan for its aPKCi inhibitor platform, a potential breakthrough in treating hedgehog pathway-dependent cancers. …
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform Read More WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the appointment of Leanne Kelly to its board of directors. Kelly, a seasoned financial executive with extensive public company experience, will …
Windtree Therapeutics Appoints Leanne Kelly to Board, Advances New Growth Strategy Read More WARRINGTON, PA — Windtree Therapeutics, Inc. announced a bold new plan to establish itself as a revenue-generating biotechnology company by acquiring small businesses with FDA-approved products. At the same time, the …
Windtree Therapeutics Unveils New Strategy to Drive Revenue Growth Read More